53 completed, 7 recruiting, 7 terminated, 6 withdrawn. 81 Phase 2, 12 Phase 3, 9 Phase 1.
Follow Testosterone: new trials by email Literature Review of Testosterone trials Research Report on Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Ranging Study to Examine TDS-Testosterone 5% Testosterone, Pump Sprayer - Hypogonadotropism | Phase 2 | Not yet recruiting | Transdermal Delivery Solutions Corp | 48 | 2027-06-01 | 2026-09-30 |
| Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream - Vulvodynia, Dyspareunia | Phase 2 / Phase 3 | Not yet recruiting | TriHealth Inc. | 44 | 2025-12-01 | 2025-12-03 |
| COMPASS - COpenhagen MenoPAuSe Study Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2) - Menopausal Osteoporosis, Bone Markers | Phase 2 | Recruiting | Martin Blomberg Jensen | 192 | 2025-10-02 | 2026-03-02 |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 400 | 2024-02-17 | 2026-10-26 |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc stereotactic ablative radiotherapy, Pluvicto, topical testosterone - Prostate Cancer | Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2023-12-14 | 2025-12-31 |
| Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill Androgel Topical Product, Placebo, Physical performance - Critical Illness | Phase 2 | Recruiting | University Hospital, Clermont-Ferrand | 600 | 2023-07-21 | 2023-10-02 |
| Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) Testosterone Cypionate, Placebo - Pain, Opioid Use | Phase 2 | Completed | Brigham and Women's Hospital | 36 | 2022-11-15 | 2026-04-15 |
| Testosterone Treatment in Men With Chronic Kidney Disease Jatenzo Pill - Hypogonadism, Male, Kidney Disease, Chronic | Phase 2 | Recruiting | St. Louis University | 20 | 2022-03-15 | 2026-04-30 |
| Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism Testosterone Undecanoate 250 MG/ML, Placebo - Opioid Use, Pain | Phase 2 | Recruiting | Brigham and Women's Hospital | 150 | 2022-01-10 | 2026-07-27 |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers High dose testosterone - Metastatic Prostate Cancer | Phase 2 | Recruiting | VA Office of Research and Development | 51 | 2021-08-31 | 2026-09-17 |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality AndroGel - Hypogonadism | Phase 2 | Completed | Lars Møller Pedersen | 7 | 2021-04-01 | 2022-11-29 |
| Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency testosterone 1.62% gel, placebo gel - Hypogonadism, Male, Cancer | Phase 2 | Active not recruiting | Seattle Institute for Biomedical and Clinical Research | 230 | 2021-01-12 | 2026-07-06 |
| Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy Testosterone cypionate - Prostate Cancer | Phase 2 | Completed | Hospital Sirio-Libanes | 20 | 2020-09-22 | 2022-08-03 |
| Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients AndroGel 16.2 mg/L - Hypermetabolism in ICU, Loss of Muscle Mass | Phase 2 | Completed | University Hospital, Clermont-Ferrand | 30 | 2019-06-27 | 2026-11-10 |
| ITT-5 Mechanisms of Spermatogenesis in Man Testosterone 1% Gel, Acyline, Dutasteride - Gonadotropin Deficiency | Phase 2 | Withdrawn | University of Washington | 2019-06-01 | 2019-12-18 | |
| Short-term Testosterone Replacement in Testicular Cancer Survivors Androgel (Testosterone gel), Placebo gel - Testicular Cancer | Phase 2 | Completed | University Medical Center Groningen | 32 | 2018-12-21 | 2024-07-30 |
| Testosterone and Long Pulse Stimulation After SCI Testosterone and LPWS, Testosterone and standard NMES - Spinal Cord Injury | Phase 2 | Completed | VA Office of Research and Development | 12 | 2018-07-01 | 2025-10-14 |
| Testosterone for Fatigue in Men With MS AndroGel 1 % Topical Gel, Placebos - Multiple Sclerosis | Phase 2 | Withdrawn | University of California, Los Angeles | 2018-07-01 | 2019-11-06 | |
| Effect of PROGRESSive Training and Teststerone in Older Frail Men testosterone, Progressive muscle training - Muscle Weakness | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 192 | 2016-11-01 | 2024-05-29 |
| Study of Testosterone vs Placebo in Testicular Cancer Survivors Testosterone, Placebos - Metabolic Syndrome, Testicular Cancer | Phase 2 / Phase 3 | Completed | Mikkel Bandak | 69 | 2016-11-01 | 2020-03-06 |
Showing 20 of 81. Sign in to see all of them.
Hypogonadism (28) · Prostatic Neoplasms (8) · Neoplasms (6) · Insulin Resistance (4) · Diabetes Mellitus, Type 2 (3) · Eunuchism (3) · Motor Activity (3) · Multiple Sclerosis (3) · Osteoporosis (3) · Pain (3) · Acquired Immunodeficiency Syndrome (2) · Anorexia Nervosa (2) · Bone Diseases, Metabolic (2) · Breast Neoplasms (2) · Depression (2)
University of Washington (9) · Repros Therapeutics Inc. (4) · VA Office of Research and Development (4) · Massachusetts General Hospital (3) · Memorial Sloan Kettering Cancer Center (3) · University of California, Los Angeles (3) · Acerus Pharmaceuticals Corporation (2) · Antares Pharma Inc. (2) · Brigham and Women's Hospital (2) · Emotional Brain NY Inc. (2) · National Institute on Aging (NIA) (2) · TesoRx Pharma, LLC (2) · University Hospital, Clermont-Ferrand (2) · University Potiguar (2) · Acrux DDS Pty Ltd (1)
United States (58) · Brazil (4) · Denmark (4) · Australia (2) · Canada (2) · France (2) · Finland (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
William J Bremner, MD, PhD (4) · Stephanie T Page, MD, PhD (3) · Sandeep Dhindsa, MD (2) · Shehzad Basaria, MD (2) · Alicia Marzal, M.D. (1) · Alvaro Morales, MD FRCSC (1) · Anne Klibanski, M.D. (1) · Anne Klibanski, MD (1) · Antonio Pellicer, Professor (1) · Ashraf Gorgey, PhD PT (1) · Cecilia Lansang, MD (1) · Craig W Spellman, DO (1)
PMID 17494097, PMID 24519196, PMID 16940442, PMID 17105798, PMID 17303493, PMID 17502467, PMID 17592924, PMID 18077826, PMID 18671877, PMID 19734776, PMID 20484472, PMID 20881067, PMID 21252493, PMID 21543538, PMID 21717386, PMID 22463890, PMID 22606232, PMID 22895351, PMID 22939385, PMID 23040523, PMID 23150682, PMID 23303450, PMID 23343764, PMID 23348398, PMID 24009246, PMID 24298851, PMID 24423356, PMID 24634831, PMID 24655871, PMID 24824900, PMID 24918945, PMID 24968251, PMID 25044085, PMID 25211297, PMID 25392748, PMID 25514427, PMID 25599449, PMID 25807408, PMID 25955224, PMID 26950683, PMID 27171844, PMID 27172434, PMID 27433905, PMID 27482750, PMID 27716209, PMID 27992261, PMID 28240622, PMID 28673265, PMID 28981994, PMID 29500160
U54HD012629 (2), U54HD042454 (2), 1UL1RR025758 (1), 2009 (1), 2017 (1), 2025 (1), I01CX002775 (1), K23DK002858 (1), K23HD045386 (1), P50GM060338 (1), R01AG018169 (1), R01AG019339 (1), R01AG037603 (1), R01AR050618 (1), R01DK052625 (1)